Dimethylphenylpiperazinium
Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H19N2 |
Molar mass | 191.298 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype.[1] One of the earliest reports on the pharmacology of DMPP, describing it as a ganglion-stimulating, hypertensive agent, came from Graham Chen and his co-workers at Parke, Davis & Co. (Now Pfizer)[2]
See also
- Phenylpiperazine
References
- ↑ Prado WA, Segalla DK (August 2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Research. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888.
- ↑ Chen G, Portman R, Wickel A (November 1951). "Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent". The Journal of Pharmacology and Experimental Therapeutics. 103 (3): 330–6. PMID 14898449.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.